Holen Sie sich die Stockscreener-App
741.85
0.69%
-5.13
Handel nachbörslich:
741.24
-0.61
-0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$746.98
Offen:
$745.99
24-Stunden-Volumen:
2.16M
Relative Volume:
0.50
Marktkapitalisierung:
$702.13B
Einnahmen:
$53.26B
Nettoeinkommen (Verlust:
$13.80B
KGV:
48.49
EPS:
15.3
Netto-Cashflow:
$-50.20M
1W Leistung:
-2.40%
1M Leistung:
+4.24%
6M Leistung:
-14.23%
1J Leistung:
-19.75%
1-Tages-Spanne:
$736.16
$746.94
1-Wochen-Bereich:
$736.16
$772.53
52-Wochen-Spanne:
$623.78
$939.30
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
741.85 | 669.64B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.69 | 425.26B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
219.99 | 393.25B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
123.00 | 237.76B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
NVO
Novo Nordisk Adr
|
58.74 | 264.56B | 45.44B | 16.18B | 9.21B | 3.634 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly announces second major investment in US manufacturing - Washington Examiner
Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy? - The Motley Fool
Eli Lilly to build $6.5B pharmaceutical factory at Houston's Generation Park - InnovationMap
Pharmaceutical giant Eli Lilly to invest over $6 billion in Houston - The American Bazaar
Eli Lilly’s strategy in motion: Beyond diabetes and obesity - Labiotech.eu
What's Going On With Eli Lilly Stock WednesdayEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly and Company invests $6.5 billion to build pharmaceutical manufacturing facility in Texas - Plant Services
Eli Lilly to Build $6.5 Billion Pharmaceutical Facility in Harris County, Texas, Bolstering Local Economy and Job Market - Hoodline
Eli Lilly to Build Second, $6.5B US Manufacturing Plant - Powder & Bulk Solids
Eli Lilly’s Phase 1 Study of LY3876602: Key Insights for Investors - TipRanks
Texas-sized investment: Eli Lilly announces $6.5bn Houston manufacturing facility - BioProcess International
Lilly to build $6.5B Houston factory for its first obesity pill - Manufacturing Dive
Lilly Investing $6.5B in Houston Manufacturing Facility - Connect CRE
Bernstein reiterates Eli Lilly stock rating with $1,100 price target - Investing.com
Big Pharma's backlash against England continues as Lilly CEO Ricks blasts country on drug pricing, investment - Fierce Pharma
Lilly to pour $6.5 billion into GLP-1 pill manufacturing site - C&EN
UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker - The Guardian
Lilly to spend $6.5bn on second of four US manufacturing facilities - PMLiVE
Eli Lilly price leans on SMA supportForecast today24-09-2025 - Economies.com
Eli Lilly's boss calls UK the 'worst' European country for drug prices - Reuters
Eli Lilly to invest $6.50bn in new Texas facility - MarketScreener
Lilly Unveils Second Facility in Manufacturing Push, Naming Texas as Site of New $6.5B Plant - BioSpace
Eli Lilly to Build $6.5B Pharmaceutical Manufacturing Facility at Generation Park in Houston, Create 600 Jobs - REBusinessOnline
Eli Lilly investing $6.5B in the Houston area - KVUE
Eli Lilly to build $6.5bn orforglipron production site in Texas - Yahoo Finance
How Will Eli Lilly’s Mounjaro Trial Results Shape Its 2025 Valuation? - Yahoo Finance
Eli Lilly CEO says U.K. ‘worst’ European country for drug prices, Reuters says - TipRanks
Eli Lilly (LLY) CEO Criticizes UK Drug Pricing Approach - GuruFocus
Lynch & Associates IN Acquires 971 Shares of Eli Lilly and Company $LLY - MarketBeat
Jim Cramer Rethinks His Bullish Stance on Eli Lilly Stock (LLY) - TipRanks
Eli Lilly CEO slams UK drug pricing: what’s behind the backlash? - TradingView
Eli Lilly CEO slams UK drug pricing policy: "The worst country in Europe" - medwatch.com
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement - TradingView
Eli Lilly invests $6.5bn in Texas to produce its oral weight-loss pill - MarketScreener
Lilly to invest $6.5bn in API manufacturing facility in Texas - Yahoo Finance
Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record highas it happened - The Guardian
Celltrion signs agreement to buy Eli Lillys U.S. plant for USD 330 mn - Tribune India
Pfizer Challenges Novo Nordisk and Eli Lilly with $7.3B Metsera Buyout - NAI500
Eli Lilly Deal In Weight Loss Drugs Trademark Suit Hits Snag - Law360
Celltrion inks agreement to buy Eli Lilly’s U.S. plant for $330 mn - 매일경제
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant - 104.1 WIKY
Lilly to build $6.5 billion manufacturing facility in Houston By Investing.com - Investing.com Australia
Eli Lilly and Co.’s $6.5B Houston site to produce oral drug for obesity, diabetes - WISH-TV
Drugmaker Eli Lilly building $6.5 billion plant in NE Houston - FOX 26 Houston
News | Drugmaker Eli Lilly to invest $6.5 billion to build largest US manufacturing campus of its kind - CoStar
Eli Lilly and Company (NYSE:LLY) Trading Down 1%Here's Why - MarketBeat
Eli Lilly and Company (LLY) Unveils $5B Virginia Facility to Ramp Up Bioconjugate and Monoclonal Antibody Production - Yahoo Finance
Lilly to build $6.5 billion pharmaceutical manufacturing facility in Houston - CW39 Houston
Eli Lilly To Build $6.5 Bln Manufacturing Plant In Texas For Obesity Pill Production - Nasdaq
Celltrion buys Eli Lilly’s New Jersey plant for $330 million - KED Global
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):